Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday. The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use. The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said. In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease. |
China's rural policy bank to increase financial support for rural revitalizationComedy films dominate as China's Spring Festival box office hits record highChina to further enhance NEV charging facilitiesChina sees over 7.2 bln interThriving logistics reflect China's economic vitalityInterview: China's economic landscape displays stable, diversified trend: economistWealthy New Yorkers are ditching idyllic Manhattan townhouses for doormanChina to further enhance NEV charging facilitiesSOEs' AI push may transform industriesNew Zealand's dairy giant looks to expand business in China